[
  {
    "ts": null,
    "headline": "Labcorp Holdings Inc. (LH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript",
    "summary": "Labcorp Holdings Inc. (LH) 44th Annual J.P.",
    "url": "https://finnhub.io/api/news?id=5a6dd01a4abc7f1bc107377683c71de01a4867fe6a08d3378f1ee4f3467450b2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768342559,
      "headline": "Labcorp Holdings Inc. (LH) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript",
      "id": 138089872,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "LH",
      "source": "SeekingAlpha",
      "summary": "Labcorp Holdings Inc. (LH) 44th Annual J.P.",
      "url": "https://finnhub.io/api/news?id=5a6dd01a4abc7f1bc107377683c71de01a4867fe6a08d3378f1ee4f3467450b2"
    }
  },
  {
    "ts": null,
    "headline": "Labcorp Expands MRD Testing for Breast, Lung and Colon Cancer Recurrence Risk",
    "summary": "Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the continued expansion of its molecular residual disease (MRD)i portfolio designed to help clinicians detect cancer recurrence earlier than traditional imaging. The expanded offerings include Labcorp Plasma Detect ID, a whole exome sequence-guided, personalized panel for patients with stage I–III breast cancer or stage I–IIIA non-small cell lung cancer, and the nationwide availability of Lab",
    "url": "https://finnhub.io/api/news?id=dc1ee03712f0330e98c682d92260c8159fbdcc8c252f6287d77eae3879010b67",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768305600,
      "headline": "Labcorp Expands MRD Testing for Breast, Lung and Colon Cancer Recurrence Risk",
      "id": 138083797,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LH",
      "source": "Yahoo",
      "summary": "Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the continued expansion of its molecular residual disease (MRD)i portfolio designed to help clinicians detect cancer recurrence earlier than traditional imaging. The expanded offerings include Labcorp Plasma Detect ID, a whole exome sequence-guided, personalized panel for patients with stage I–III breast cancer or stage I–IIIA non-small cell lung cancer, and the nationwide availability of Lab",
      "url": "https://finnhub.io/api/news?id=dc1ee03712f0330e98c682d92260c8159fbdcc8c252f6287d77eae3879010b67"
    }
  },
  {
    "ts": null,
    "headline": "Assessing Labcorp Holdings (LH) Valuation After A Recent 10.5% Three Month Share Price Decline",
    "summary": "Recent trading in Labcorp Holdings (LH) has drawn attention after the stock showed a 10.5% decline over the past 3 months, prompting investors to reassess its current valuation and long term return profile. See our latest analysis for Labcorp Holdings. The recent 10.5% 3 month share price decline sits against a relatively steady year to date share price return of around flat, while the 1 year total shareholder return of 8.15% suggests momentum has cooled rather than collapsed. If Labcorp’s...",
    "url": "https://finnhub.io/api/news?id=a06443b1ffad4b744f06034c075780b8475370a98d6aa746312eb359eac4c402",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768288036,
      "headline": "Assessing Labcorp Holdings (LH) Valuation After A Recent 10.5% Three Month Share Price Decline",
      "id": 138083798,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LH",
      "source": "Yahoo",
      "summary": "Recent trading in Labcorp Holdings (LH) has drawn attention after the stock showed a 10.5% decline over the past 3 months, prompting investors to reassess its current valuation and long term return profile. See our latest analysis for Labcorp Holdings. The recent 10.5% 3 month share price decline sits against a relatively steady year to date share price return of around flat, while the 1 year total shareholder return of 8.15% suggests momentum has cooled rather than collapsed. If Labcorp’s...",
      "url": "https://finnhub.io/api/news?id=a06443b1ffad4b744f06034c075780b8475370a98d6aa746312eb359eac4c402"
    }
  },
  {
    "ts": null,
    "headline": "3 Value Stocks We Think Twice About",
    "summary": "The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.",
    "url": "https://finnhub.io/api/news?id=dde017e41bbb09b2fac4730381a0e354804d22f156cf86f08ddc3702b6f2e5ac",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768278825,
      "headline": "3 Value Stocks We Think Twice About",
      "id": 138084692,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LH",
      "source": "Yahoo",
      "summary": "The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer. However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.",
      "url": "https://finnhub.io/api/news?id=dde017e41bbb09b2fac4730381a0e354804d22f156cf86f08ddc3702b6f2e5ac"
    }
  },
  {
    "ts": null,
    "headline": "Best Testosterone Replacement Therapy (TRT) 2026: Taurus Meds Consumer Analysis Examines Online TRT Access and At-Home Testosterone Treatment Options",
    "summary": "Consumer Report Details Low Testosterone Treatment Costs, LabCorp and Quest Lab Testing, Licensed Provider Access, and What Men Need to Know Before Starting Online TRTWILMINGTON, DE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only. It is not medical advice. Testosterone replacement therapy requires evaluation by a licensed healthcare provider. If you access services through links in this article, a commission may be earned at no additional cost to yo",
    "url": "https://finnhub.io/api/news?id=cb61d855fba9a557bef6d207eab07c899b18daae7f208e45d5c057dacefdd3c5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1768262520,
      "headline": "Best Testosterone Replacement Therapy (TRT) 2026: Taurus Meds Consumer Analysis Examines Online TRT Access and At-Home Testosterone Treatment Options",
      "id": 138083799,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LH",
      "source": "Yahoo",
      "summary": "Consumer Report Details Low Testosterone Treatment Costs, LabCorp and Quest Lab Testing, Licensed Provider Access, and What Men Need to Know Before Starting Online TRTWILMINGTON, DE, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Disclaimer: This article is for informational purposes only. It is not medical advice. Testosterone replacement therapy requires evaluation by a licensed healthcare provider. If you access services through links in this article, a commission may be earned at no additional cost to yo",
      "url": "https://finnhub.io/api/news?id=cb61d855fba9a557bef6d207eab07c899b18daae7f208e45d5c057dacefdd3c5"
    }
  }
]